What was checked
A cancer vaccine just added 9 months to median survival for leukemia patients... on the vaccine alone, median survival was 24 months vs 14.7
Assessment summary
AccurateThe Phase 3 REGAL trial of galinpepimut-S (GPS) showed median overall survival of 24.0 months with the vaccine versus 14.7 months with standard treatment, a difference of exactly 9 months.